regimen for remission induction. A recent study demonstrated that a reduced-dose glucocorticoid regimen provided a similar benefit compared to a standarddose regimen for the composite outcome of ESRD or death, and was associated with a decreased risk of infection http://onlin e libr ary.wiley.com/doi/10.1002/acr.24634/ abstract Remission induction for active, nonsevere disease Recommendation: For patients with active, nonsevere GPA, we conditionally recommend initiating treatment with